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ABSTRACT
Background. Recurrence rates of intrahepatic cholangiocarcinoma (iCCA) after curative hepatectomy are as high
as 50% to 70%, and about half of these recurrences occur
within 2 years. This systematic review aims to define
prognostic factors (PFs) for early recurrence (ER, within 24
months) and 24-month disease-free survival (DFS) after
curative-intent iCCA resections.
Methods. Systematic searching was performed from
database inception to 14 January 2021. Duplicate independent review and data extraction were performed. Data
on 13 predefined PFs were collected. Meta-analysis was
performed on PFs for ER and summarized using forest
plots. The Quality in Prognostic Factor Studies tool was
used for risk-of-bias assessment.
Results. The study enrolled 10 studies comprising 4158
patients during an accrual period ranging from 1990 to
2016. In the risk-of-bias assessment of patients who
experienced ER after curative-intent iCCA resection, six
studies were rated as low risk and four as moderate risk
(49.6%; 95% confidence interval [CI], 49.2–50.0). Nine
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studies were pooled for meta-analysis. Of the postoperative
PFs, multiple tumors, microvascular invasion, macrovascular invasion, lymph node metastasis, and R1 resection
were associated with an increased hazard for ER or a
reduced 24-month DFS, and the opposite was observed for
receipt of adjuvant chemo/radiation therapy. Of the preoperative factors, cirrhosis, sex, HBV status were not
associated with ER or 24-month DFS.
Conclusion. The findings from this systematic review
could allow for improved surveillance, prognostication,
and treatment decision-making for patients with
resectable iCCAs. Further well-designed prospective studies are needed to explore prognostic factors for iCCA ER
with a focus on preoperative variables.

Intrahepatic cholangiocarcinoma (iCCA) is the second
most common type of primary liver cancer, with an incidence of 0.85 per 100,000 annually.1,2 Although iCCA is a
rare and complex disease, its incidence in in North
America has increased almost five-fold, and the reasons for
this increase are not clear.3,4 Surgery remains the mainstay
therapy for curative intent, but only about 20% of iCCAs
are surgically resectable at the time of diagnosis. In addition, the recurrence rates after liver resection (LR) are
exceedingly high, reaching 50–70% and leaving limited
treatment options.5–7 In fact, most of the recurrence occurs
relatively early, about 25% within 6 months and 50%
within 2 years after surgery.8
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In the current literature, the definition of early recurrence (ER) after curative-intent surgery for iCCA varies
from 12 to 24 months.9,10 The identified risk factors for ER
of iCCA are age, cirrhosis, hepatitis B (HBV), carbohydrate antigen 19-9 (CA19-9), tumor size, number of tumor
lesions, and lymph node metastases (LNM).8–11 The cited
studies are limited by their small samples, with heterogenicity observed in the measured choice of prognostic
factors.12–14 Moreover, none of the few iCCA recurrence
risk stratification tools described in the literature provides a
comprehensive summary of the prognostic factors for
ER.15–21 The high recurrence rates underscore the need for
better identification of patients with a greater risk for ER
both before and after surgery who might benefit from
alternative treatment sequencing strategies such as neoadjuvant and/or adjuvant chemotherapy.22
The primary objective of this systematic review and
meta-analysis was to define prognostic factors for ER,
within 24 months after surgery, in adult patients undergoing curative-intent resection of iCCA. The secondary
objective was to define prognostic factors for 24-month
disease-free survival (DFS) after curative-intent resection
of iCCA. This report provides the most up-to-date evidence
for identification of patients at highest risk for iCCA ER
after curative-intent surgery.
METHODS
Protocol and Reporting
The protocol for this study was registered with PROSPERO (ID 247079).23 This review was conducted
according to the Cochrane Collaboration handbook guidelines and reported following the Preferred Reporting Items
for Systematic Reviews and Meta-analyses (PRISMA)
statement.
Eligibility Criteria
The included articles were randomized/quasi-randomized trials and cohort studies that evaluated the effect of
any prognostic factor on the recurrence of iCCA within 24
months after curative intent surgery among adults 18 years
of age or older. Studies were considered eligible for
inclusion if they reported the absolute rate of iCCA
recurrence stratified by a prognostic factor within 24
months after curative-intent surgery (primary outcome), or
if they reported the absolute rate of other common cancer
outcome measures such as DFS or recurrence-free survival
(subsequently denoted as DFS) within 24 months after
curative-intent surgery. The study excluded review articles,
meta-analyses, case series, and cross-sectional studies, as

well as research in progress, conference proceedings/abstracts, dissertations/theses, and book chapters.
The included studies were specific to histologically
confirmed, de novo iCCA. Studies evaluating other common hepatobiliary malignancies such as extrahepatic
cholangiocarcinoma, hilar cholangiocarcinoma, gallbladder cancer, hepatocellular carcinoma, or concomitant
diseases were excluded.
Information Sources and Search Strategy
An academic hospital information specialist (M.E.)
developed the search strategies in conjunction with all the
authors (Appendix 1). Key search terms were determined
from a scoping search of the literature and consultation
with experts in the field. The databases Medline, Medline
In-Process/ePubs, Embase, Cochrane Central Register of
Controlled Trials (CCTR), and the Cochrane Database of
Systematic Reviews (CDSR) all were searched via the
Ovid platform from inception of the review to 14 January
2021. The search component blocks used were ‘‘cholangiocarcinoma’’ and ‘‘intrahepatic’’ and ‘‘recurrence’’ and
‘‘surgery,’’ and ‘‘early.’’ All the components included
controlled vocabulary and text word terms. The searches
were limited to humans and adults, with conference
materials removed when possible. No language limits were
applied. Citations of all the included studies were searched,
and the first 100 hits from Google Scholar also were
searched manually for augmenting studies. No gray literature was searched. Plans were made to contact study
authors only if clarification was needed.
Study Selection Process
Article abstracts identified in the search were independently screened by two authors (W.J.C. and P.J.W.), and
those not meeting the eligibility criteria were excluded
(Fig. 1). The same two reviewers then assessed the full-text
articles. Reviewer disagreements were resolved by consensus and involvement with a third reviewer (G.S.) as
needed. Covidence systematic review software (Veritas
Health Innovation, Melbourne, Australia) was used for
screening and full-text selections.
Data Collection Process
The included studies had baseline characteristics and
outcome data extracted in duplicate using a piloted, standardized template designed by the authors (W.J.C. and
P.J.W.). The data were entered and maintained in Microsoft Excel (Microsoft, Redmond, WA, USA), and accuracy
was verified by comparisons between authors.
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FIG. 1 PRISMA
flowchart version 2020

Included

Screening

Identification

Identification of studies via databases and registers

Records identified from*:
Databases and registers
(n = 940)

Records removed before
screening:
Duplicate records removed
(n = 242)

Abstract records screened
(n = 698)

Abstract records excluded**
(n = 585)

Reports sought for retrieval
(n = 113)

Reports not retrieved
(n = 7)

Full text reports assessed for
eligibility
(n = 106)

Full text reports excluded:
(n = 96)
Wrong outcome (n = 53)
Wrong prognostic factor (n = 32)
Wrong patient population (n = 9)
Protocol only (n=1)
Wrong study design (n=1)

Studies included in review
(n = 10)

Data Items
The primary outcome of interest in this review was ER,
defined as the recurrence rate of iCCA within 24 months
after curative-intent surgery. The secondary outcomes of
interest were other composite measures of iCCA recurrence and survival within 24 months after curative-intent
surgery and included DFS. A list of 13 prognostic factors
was developed a priori based on expert consensus and a
scoping review of the literature. Data regarding these
variables were sought for each included study, and missing
data were noted. These factors included patient demographics (age [continuous], sex [binary]), health measures
(presence of hepatitis B and/or C infection [binary], cirrhosis [binary]), tumor factors (CA19-9 level [continuous],

tumor size [binary, [5 vs. B5 cm], tumor number [continuous], tumor differentiation [poor vs moderate or good
tumor differentiation], microvascular invasion [binary],
macrovascular invasion [binary], and lymph node metastasis [binary]), and treatment factors (R0 resection [binary]
and adjuvant chemotherapy or radiation therapy [binary]).
Age, sex, hepatitis B virus (HBV) and/or hepatitis C virus
(HCV), cirrhosis, and CA19-9 were categorized as preoperative prognostic factors. Tumor size, tumor number,
tumor differentiation, microvascular invasion, macrovascular invasion, LNM, R0 resection, and adjuvant
chemotherapy or radiation therapy were categorized as
postoperative prognostic factors. Continuous variables
were summarized as median (interquartile range) values
and categorical variables as percentages.
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Study Risk-of-Bias Assessment

RESULTS

The risk of bias was assessed for each included study by
two independent reviewers (W.J.C. and P.J.W.) using the
Quality in Prognostic Factor Studies (QUIPS) tool.24,25 The
QUIPS tool comprises six domains used to classify the risk
of bias of prognostic factor studies.24 These domains are
study participation, study attrition, prognostic factor measurement, outcome measurement, adjustment for other
prognostic factors, and statistical analysis and reporting.
Each domain was assigned a risk-of-bias rating (high,
moderate, or low), and an overall rating was subsequently
applied (a rating of moderate/high risk of bias C1
domain[s] resulted in an overall rating of moderate/high
risk of bias).25 Disagreements between reviewers were
resolved by discussion and consensus.

Study Selection

Synthesis of Results
If a prognostic factor associated with the primary or
secondary outcome (recurrence or DFS within 24 months)
was reported by two or more included studies, then that
factor was considered for meta-analysis. When synthesis
for extracted data was achievable, Review Manager (v5.3.
Copenhagen: The Nordic Cochrane Centre, The Cochrane
Collaboration, 2014) was used to perform meta-analyses.26
The adjusted summary effects (either as odds ratio [OR] or
hazard ratio [HR]) measured in their originally reported
form were used. Unadjusted summary effects were used if
adjusted summary effects were not available.
Statistical heterogeneity was assessed using the I2 statistical estimate, and a random-effects model was used in
anticipation of heterogeneity across studies. The study
categorized I2 as follows: 40% as low, 40–60% as moderate, 60–75% as substantial, and 75–100% as considerable
heterogeneity. Prognostic factors were classified as either
preoperative or postoperative, and forest plots were generated to display results.
For the secondary outcomes, HRs were estimated using
the Parmar method at 24 months in the DFS Kaplan-Meier
curves.27 If studies were found using the same database, the
degree of the database overlap was assessed based on
sample size and study duration. For near complete overlap,
the effect estimate was extracted from only one study in the
order of preference of reporting (1: adjusted effect estimate; 2: analysis of a larger and more recent patient
sample), and sensitivity analysis was conducted.
Reporting Bias
If prognostic factors were identified in more than 10
studies, the risk of reporting or publication bias was
assessed using funnel plots.28

Our initial search strategy identified 940 studies, 242 of
which were duplicates. After the initial title and abstract
screening, 585 abstracts were excluded for not meeting our
inclusion criteria. A total of 113 full-text articles were
sought for retrieval, and 7 reports could not be retrieved
with an information specialist’s help. Of the 106 full-text
articles screened, 96 were excluded. The reasons for the
exclusions are demonstrated in the PRISMA
flowchart (Fig. 1). Studies excluded for the reason of
‘‘wrong prognostic factor’’ mainly consisted of basic science, genetic, and radiologic analyses. The current study
included 10 studies. Four studies met our primary objective
of reporting ER,8–10,29 and six studies met our secondary
objective of reporting 24-month DFS.30–35
Study Characteristics
The characteristics of the 10 studies meeting our
objectives are summarized in Table 1. These studies
involved 4158 patients.8–10,29–35 Nine of the studies were
retrospective cohort studies, and the remaining study was a
prospective cohort study. The publication years of the
studies ranged from 2010 to 2020.
All the patients underwent curative-intent surgery for
iCCA. Of the 10 studies, 4 were from Asia,9,10,30 2 were
from Europe,31,32 1 was from Australia,33 and 3 used the
same multicenter database from which the research was
conducted in the United States.8,29,34 The patient accrual
period for these 10 studies ranged from 1990 to 2016. The
median patient follow-up period reported ranged from 19
to 44 months.8,9,29 The three studies that used the same
multicenter database comprised an average of 967 patients
(range, 880–1089 patients).8,29,34
Definition and Reporting of Early Recurrence
Of the four studies that met our primary objective, two
used 24 months from the time of surgery as the cutoff time
point to define ER.9,29 Wang et al.10 used 12 months as the
cutoff for ER, and Tsilimigras et al.8 used a cutoff of 6
months to define ‘‘very early recurrence (VER). More than
49.6% (95% confidence interval [CI], 49.2–50.0%) of the
patients experienced ER (within 12–24 months), and 22.3%
experienced VER after curative-intent iCCA resection. The
overall iCCA recurrence rate was reported as 59.3–78.8%.
Of the patients who experienced ER, the 5-year overall
survival (OS) ranged from 8.0 to 11.6%.8–10

Study
period

Study
design

Inclusion criteria

Exclusion criteria

2005–2009

2005-2011

1990–2016

Wang10 China

Yang9 China

Zhang29 USA,
multicenter

RC

RC

RC

RC

Curative-intent
hepatectomy, histologic
iCCA

Curative hepatectomy

Curative hepatectomy,
pathology iCCA

Curative-intent
hepatectomy, histologic
iCCA

Extrahepatic metastasis, palliative resection, ablation,
or intra-arterial therapy only, lost to f/u, missing
data

Preoperative TACE, RFA, PEI

HCC ? iCCA, who died during f/u, incomplete data

Macroscopically positive surgical margins, lack of f/u
data, death of loss to f/u without recurrence within
6 months

1990–2015

2004–2009

2001–2015

1997–2008

1990–2009

Hu34 USA,
multicenter

Luvira30
Thailand

Nickkholgh32
Germany

Nuzzo31 Italy

Saxena33
Australia

RC

RC

PC

RC

RC

RC

Histologic iCCA referred

Hepatectomy, histologic
iCCA

Hepatectomy, histologic
iCCA

Curative-intent
hepatectomy, histologic
mass-forming iCCA

Curative-intent
hepatectomy, histologic
iCCA

Curative hepatectomy

Perihilar tumors

Primary extrahepatic tumors or metastases

No TNM classification, combined HCC, papillary or
mucinous adenocarcinoma

Periductal infiltration or intraductal tumor

Palliative or R2 resection, ablation, or intra-arterial
therapy, extrahepatic metastasis

Combined HCC-CCA, intraductal growing type,
periductal infiltrating, R1 resection

88

55

190

50

1,089

292

933

322

259

880

No. of
patients

31

28

19

–

35

–

22

44

–

24

Median
followup
(months)

–

6

–

–

–

–

24

24

12

6

ER
definition
(months)

68.0

61.8

45.8

80.0

66.9

52.3

73.4

59.3

78.8

–

Overall
recurrence
rate
(%)

–

38.2

–

–

–

–

57.9

52.2

50.2

22.3

ER
rate
(%)

–

–

–

–

–

–

-

11.6

8.0

8.9

5-year OS
in ER
group
(%)

CCA, cholangiocarcinoma; DFS, disease-free survival; ER, early recurrence; f/u, follow up; HCC, hepatocellular carcinoma; iCCA, intrahepatic cholangiocarcinoma; med, median; OS, overall
survival; PC, prospective cohort; PEI, percutaneous ethanol injection; RC, retrospective cohort; RFA, radiofrequency ablation; any missing or not applicable parts were marked with ‘‘–’’;
TACE, transarterial chemoembolization; TNM, tumor-node-metastasis

2003–2012

Ahn35 Korea

Secondary objective: 24 months DFS: summary report for all patients in the study

1990–2016

Tsilimigras8
USA,
multicenter

Primary objective: early recurrence: summary report for patients in the ER group

First author
(year)
country)

TABLE 1 Included study characteristics
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Prognostic Factors

Meta-Analysis for Prognostic Factors

Before the review search, 13 prognostic factors of
interest were identified. The 13 main prognostic factors are
summarized in Tables 2 and 3, divided into pre- and
postoperative factors. In the overall patient groups, the
median age ranged from 41 to 63 years, and the proportion
of patients with cirrhosis ranged from 11.5 to 31.7%.
Multiple tumors were noted in 14.0% to 25.3% of the
patients, and 4.7–33.2% of the patients had microvascular
invasion. The presence of lymph node metastasis ranged
from 15.5 to 64%.8–10,29,30,33 The R0 rate for the ER group
was reported in two studies and ranged from 30.0 to
87.4%.8,29 A positive HBV status was reported in three
studies, up to 22.8–40.5%.9,10,31 Postoperative poor tumor
differentiation ranged from 10.0 to 28.0% over five
studies.8,9,29,30,33

Nine studies with a total of 2189 patients were eligible
for the meta-analysis, providing the estimated effects for at
least one of the pre-specified prognostic factors for the
correct recurrence analysis period (recurrence within 24
months or 24-month DFS).9,10,29–35 One study was excluded from the meta-analysis for two reasons: (1) sole
reporting of summary measures in operating rooms because
it could not be pooled with the other studies that reported
estimates as HRs and (2) overlapping database with two
other studies that also investigated the same prognostic
factors.29,34
Adjusted estimates were used wherever possible, and all
results were presented as forest plots. The postoperative
prognostic factors pooled by HRs included multiple
tumors, poor tumor differentiation, microvascular invasion,
macrovascular invasion, LNM, adjuvant chemotherapy
(CT)/radiation therapy (RT), tumor size ([5 vs. B5cm),
and R1 versus R0 resection (Fig. 2). The preoperative
prognostic factors pooled by HRs were cirrhosis, sex, and
HBV (Fig. 3).f The postoperative prognostic factors associated with an increased hazard of ER were multiple
tumors (HR, 1.60; 95% CI, 1.09–2.37; I2 = 21%),
microvascular invasion (HR, 1.57; 95% CI, 1.17–2.10; I2 =
0%), macrovascular invasion (HR, 1.76; 95% CI,
1.46–2.13; I2 = 0%), LNM (HR, 1.42; 95% CI, 1.17–1.71;
I2 = 0%), and R1 resection (HR, 1.77; 95% CI, 1.29–2.43;
I2 = 0%]), whereas a reduced ER hazard was associated
with adjuvant CT/RT (HR, 0.68; 95% CI, 0.49–0.93; I2 =
0%). From the two studies included in the adjuvant CT/RT

Assessment on Risk of Bias in Studies
The risk-of-bias assessment result is presented in
Table 4. Using the QUIPS tool,24 10 studies meeting the
primary and secondary objectives were rated.8–10,29 Six
studies were rated as having an overall low risk of
bias,8,29–31,33,34 whereas four studies were rated as having
moderate risk of bias.9,10,32,35 No ratings of high risk were
made, and no studies were excluded at this stage. Based on
a moderate risk of bias present in at least one category, the
overall rating of four studies was upgraded to moderate
risk.

TABLE 2 Preoperative prognostic factors for ER or 24-month DFS after curative-intent iCCA resection
First author (year) country

Median age
(years)

Male
(%)

HBV/HCV
(%)

Cirrhosis
(%)

CA19-9

Primary objective: early recurrence: summary report for patients in the ER group
Tsilimigras8 USA (multicenter)

55

58.7

–

19.4

60.9 U/ml, med

Wang10 China

55

67.2

22.8/–

31.7

52.1%, [37 U/L

Yang9 China

41

61.9

40.5/0.7

27.1

36.5%, [89 U/ml

Zhang29 USA (multicenter)

58

58.0

–

11.5

53.8 U/ml, med

Secondary objective: 24 months DFS: summary report for all patients in the study
Ahn35 Korea

–

–

–

–

–

Hu34 USA (multicenter)
Luvira30 Thailand

–
57

–
50.0

–
–

–
–

–

Nickkholgh32 Germany

63

56.3

–

–

32.0 (U/ml, med, overall)

Nuzzo

31

Italy

Saxena33 Australia

–

–

61

53.0

40.0/–

–

–

–

–

–

CA19-9, carbohydrate antigen 19-9; DFS, disease-free survival; ER, early recurrence; HBV, hepatitis B virus; HCC, hepatocellular carcinoma;
HCV, hepatitis C virus, any missing or not applicable parts were marked with ‘‘–’’; iCCA, intrahepatic cholangiocarcinoma; med, median

Systematic Review for iCCA Early Recurrence
TABLE 3 Postoperative prognostic factors for ER or 2-year DFS after curative-intent iCCA resection
First author (year)
country

Tumor
size
(cm)

Single
tumor
(%)

Poor tumor
differentiation
(%)

Microvascular
invasion
(%)

Macrovascular
invasion
(%)

LNM
(%)

R0
(%)

Adjuvant
CT/RT
(%)

Primary objective: early recurrence: summary report for patients in the ER recurrence group
Tsilimigras8 USA
(multicenter)
Wang10 China

7.0 (med)

74.7

17.0

33.2

11.7

27.0

83.7

29.8

53.3%,
[5cm

84.6

–

4.7

7.0

15.5

–

–

Yang9 China

56.2%,
[5cm

76.6

21.4

14.0

–

18.4

–

–

12.0

21.7

87.4

36.5

–

Zhang29 USA
6.5 (med) 77.8
18.5
28.7
(multicenter)
Secondary objective: 24 months DFS: summary report for all patients in the study
Ahn35 Korea

—

–

–

–

–

–

–

Hu34 USA (multicenter)

—

–

–

–

–

–

–

–

Luvira30 Thailand

6.5
(mean)

86.0

10.0

–

–

64.0

50.0

32.0

Nickkholgh32 Germany

5.8 (med)

–

–

–

–

–

64.6

30.5

Nuzzo (2010) Italy

—

–

–

–

–

–

–

–

Saxena33 Australia

—

–

28.0

–

–

28.0

30.0

–

CT, chemotherapy; DFS, disease-free survival; ER, early recurrence; iCCA, intrahepatic cholangiocarcinoma; LNM, lymph node metastasis; med,
median; R0, negative margin resection; RT, radiation therapy; any missing or not applicable parts were marked with ‘‘–’’

analysis, the indications, types, and regimen of adjuvant
CT/RT were not reported.29,30
Of the prognostic factors analyzed, only microvascular
invasion was studied in two almost completely overlapping
database studies.29,34 Because only one of these studies
reported the adjusted effect estimate of microvascular
invasion, the adjusted effect size was used for pooling, and
sensitivity analysis was performed with the study reporting
unadjusted effect estimate (Fig. S1). No preoperative
prognostic factors such as cirrhosis (HR, 0.89; 95% CI,
0.69–1.16; I2 = 28%), male sex (HR, 0.90; 95% CI,
0.70–1.14; I2 = 0%), and HBV status (HR, 0.78; 95% CI,
0.50–1.21; I2 = 76%), were associated with ER. All but one
(HBV) meta-analyzed prognostic factor group were
reported as having low heterogeneity (I2 \40%). The HBV
(I2 = 76%) group had substantial heterogeneity. A subgroup analysis could not be performed for the HBV group
due to a low number of available studies (n = 3).
Reporting Bias
Publication bias could not be assessed due to a low
number of studies (having fewer than 10 studies per metaanalyzed prognostic factors).

Sensitivity Analyses
The meta-analysis for microvascular invasion was
repeated for sensitivity analysis because two studies
(Zhang et al.29 and Hu et al.34) had an overlapping database. The meta-analysis for microvascular invasion was
repeated selectively using effect size from the Zhang
et al.29 study only and the Hu et al.34 study only (Fig. S1).
The statistical significance and the effect estimate of the
pooled microvascular invasion remained unchanged (HR,
1.56; 95% CI, 1.17–2.10; I2 = 0% and HR, 1.57; 95% CI,
1.34–1.83; I2 = 0%, respectively).
DISCUSSION
The current systematic review and meta-analysis summarize the prognostic factors for ER (recurrence within 24
months) and 24-month DFS after curative-intent iCCA
resection. Based on the studies included in the review, the
definition of ER was defined as recurrence within a range
of 12 to 24 months after curative-intent surgery.8–10,29
After curative-intent iCCA resection, 49.6% (95% CI,
49.2–50.0%) of patients experienced ER.9,10,29 Of the 10
included studies, 9 were pooled for meta-analysis of the
eligible prognostic factors. Of the postoperative prognostic
factors, multiple tumors, microvascular invasion,
macrovascular invasion, LNM, and R1 were associated
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TABLE 4 Risk of bias assessment using Quality in Prognostic factor Studies (QUIPS) tool for the included studies
First author

1. Study
participation

2. Study
attrition

3. PF
measurement

4. Outcome
measurement

5. Adjustment for
other PF

6. Statistical analysis and
reporting

Overall

Tsilimigras
et al.

Low

Low

Low

Low

Low

Low

Low

Wang et al.

Low

Moda

Low

Low

Low

Low

Mod

Yang et al.
Zhang et al.

Low
Low

Low
Low

Low
Low

Modb
Low

Low
Low

Low
Low

Mod
Low

Ahn et al.

Low

Moda

Low

Low

Low

Low

Mod

Hu et al.

Low

Low

Low

Low

Low

Low

Low

Luvira et al.

Low

Low

Low

Low

Low

Low

Low

Nickkholgh
et al.

Low

Moda

Low

Low

Low

Low

Mod

Nuzzo et al.

Low

Low

Low

Low

Low

Low

Low

Saxena et al.

Low

Low

Low

Low

Low

Low

Low

Mod, moderate; PF, prognostic factor
a

Lacks reporting of exact study attrition rate

b

Lacks measurement methods for the cancer recurrence.

with an increased hazard for ER or reduced 24-month DFS,
whereas receipt of adjuvant chemotherapy/radiation therapy showed the opposite result. Of the preoperative factors,
cirrhosis, sex, and HBV status were not associated with ER
or 24-month DFS.
This is the first systematic review and meta-analysis to
summarize prognostic factors for ER together with
24-month DFS after curative-intent iCCA resection. The
ER definition from the four studies ranged from 12 to 24
months, consistent with the studies of other hepatobiliary
cancers such as hepatocellular carcinoma or distal
cholangiocarcinoma.8–10,29,36,37 However, the measured
prognostic factors differed across the included studies, with
varying adjusted and unadjusted analyses. The rare nature
of the disease, the relatively novel concept of ER, and the
majority of published studies from single-center populations may have been the reasons for such observed
heterogenicity.38
After pooling of all data for meta-analysis using 2189
patients, we showed how only the postoperative prognostic
factors remained associated with ER or 24-month DFS,
whereas none of the pooled preoperative factors were
associated with ER. All these postoperative prognostic
factors were those available from the final surgical
pathology report (tumor numbers, microvascular invasion,
macrovascular invasion, LNM, R0 resection) and previously shown to be associated with worse 5-year OS after
curative-intent iCCA resections.38 Only adjuvant
chemotherapy or radiation therapy was shown to be protective for ER, generally supporting the per protocol
findings of the BILCAP study.39 Our findings of these

postoperative prognostic factors may be helpful in two
ways: (1) by helping to better identify a population at
higher risk of ER after iCCA resection and (2) by providing
an opportunity to design trials to explore targeted treatments in the adjuvant settings.40
The results from this systematic review and meta-analysis narrowed the knowledge gap by offering some
prognostic factors that might play a vital role in the ER of
iCCA after resection and highlighted the scarcity of
available preoperative prognostic factors. The pooled preoperative prognostic factors of this meta-analysis were
limited to only three variables (sex, cirrhosis, HBV). Other
preoperative prognostic factors have been previously
evaluated, such as serum biomarkers (i.e., neutrophil-tolymphocyte ratio [NLR]) often sought to augment survival
risk stratification tools for patients before undergoing
major abdominal liver surgery for iCCA.15,18 However,
these types of serum biomarkers have not been studied in
the context of early iCCA recurrence. Furthermore, there
are studies using features of radiomics to develop preoperative nomograms to better predict ER of iCCA.41,42
Building a strong library of preoperative prognostic factors
for the ER of iCCA will facilitate the design of future
prospective studies that could aid in deciding whether to
offer neoadjuvant treatments to improve oncologic outcomes for these patients.
This review had several limitations. A small number of
studies (n = 10) were included, which might have caused a
bias toward the null hypothesis in the quantitative synthesis. To mitigate this, adjusted estimates were used
preferentially in the pooling of data. However, when
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Hazard Ratio
Study or Subgroup
log[Hazard Ratio]
SE Weight IV, Random, 95% CI
1.1.1 Multiple Tumors
Wang 2019
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Yang 2019
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Zhang 2017
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Subtotal (95% CI)
100.0%
1.60 [1.09, 2.37]
2
2
2
Heterogeneity: Tau = 0.03; Chi = 2.53, df = 2 (P = 0.28); I = 21%
Test for overall effect: Z = 2.38 (P = 0.02)

Hazard Ratio
IV, Random, 95% CI

1.1.2 Poor tumor differentiation
Yang 2019
1.11 [0.82, 1.51]
0.1044 0.1576 70.6%
Zhang 2017
0.1222 0.2443 29.4%
1.13 [0.70, 1.82]
Subtotal (95% CI)
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Heterogeneity: Tau2 = 0.00; Chi2 = 0.00, df = 1 (P = 0.95); I2 = 0%
Test for overall effect: Z = 0.83 (P = 0.41)
1.1.3 Microvascular invasion
Wang 2019
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Test for overall effect: Z = 2.98 (P = 0.003)
1.1.4 Macrovascular invasion
Hu 2018
0.5365 0.1021 87.9%
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Subtotal (95% CI)
100.0%
2
2
2
Heterogeneity: Tau = 0.00; Chi = 0.77, df = 1 (P = 0.38); I = 0%
Test for overall effect: Z = 5.93 (P < 0.00001)
1.1.5 Lymph Node Metastasis (LNM)
1.58 [0.65, 3.84]
Nuzzo 2010
0.4574 0.4532
4.4%
1.59 [0.94, 2.68]
Wang 2019
0.4644 0.2669 12.8%
1.56 [1.09, 2.22]
Yang 2019
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1.30 [1.01, 1.67]
Zhang 2017
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100.0%
Subtotal (95% CI)
2
2
2
Heterogeneity: Tau = 0.00; Chi = 0.97, df = 3 (P = 0.81); I = 0%
Test for overall effect: Z = 3.64 (P = 0.0003)
1.1.6 Adjuvant Chemo/Radiation Therapy
– 0.3711 0.2911 30.3%
0.69 [0.39, 1.22]
Luvira 2016
– 0.4005 0.1919 69.7%
0.67 [0.46, 0.98]
Zhang 2017
100.0%
0.68 [0.49, 0.93]
Subtotal (95% CI)
Heterogeneity: Tau2 = 0.00; Chi2 = 0.01, df = 1 (P = 0.93); I2 = 0%
Test for overall effect: Z = 2.44 (P = 0.01)
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1.17 [0.86, 1.59]
Yang 2019
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100.0%
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Subtotal (95% CI)
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Test for overall effect: Z = 1.64 (P = 0.10)
1.1.8 R1 positive margin
0.4637 0.2574 40.0%
1.59 [0.96, 2.63]
Luvira 2016
1.70 [1.09, 2.65]
0.5306 0.2268 51.5%
Nickkholgh 2019
3.71 [1.24, 11.10]
1.311 0.5592
8.5%
Saxena 2010
100.0%
1.77 [1.29, 2.43]
Subtotal (95% CI)
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Test for overall effect: Z = 3.50 (P = 0.0005)
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FIG. 2 Forest plots of pooled postoperative prognostic factors from studies reporting early recurrence or 2-year DFS after curative-intent
intrahepatic cholangiocarcinoma (iCCA) resection

adjusted estimates are used from multivariable models
including both pre- and postoperative factors, a potential

bias toward the postoperative factors might occur, resulting
in a stronger association with recurrence because the
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Hazard Ratio
Study or Subgroup
log[Hazard Ratio]
SE Weight IV, Random, 95% CI
1.2.1 Cirrhosis
0.73 [0.50, 1.08]
– 0.3106 0.1993 32.5%
Wang 2019
1.11 [0.79, 1.55]
0.1026
0.17 40.5%
Yang 2019
0.81 [0.52, 1.26]
Zhang 2017
– 0.2107 0.2261 26.9%
0.89 [0.69, 1.16]
100.0%
Subtotal (95% CI)
Heterogeneity: Tau2 = 0.02; Chi2 = 2.77, df = 2 (P = 0.25); I2 = 28%
Test for overall effect: Z = 0.87 (P = 0.38)

Hazard Ratio
IV, Random, 95% CI

1.2.6 Male
0.91 [0.63, 1.33]
Wang 2019
– 0.0899 0.1915 40.9%
Yang 2019
– 0.1233 0.1592 59.1%
0.88 [0.65, 1.21]
0.90 [0.70, 1.14]
100.0%
Subtotal (95% CI)
Heterogeneity: Tau2 = 0.00; Chi2 = 0.02, df = 1 (P = 0.89); I2 = 0%
Test for overall effect: Z = 0.90 (P = 0.37)
1.2.7 Hepatitis B Viral positive
0.207 0.2592 28.3%
1.23 [0.74, 2.04]
Ahn 2016
– 0.6675 0.1793 34.9%
0.51 [0.36, 0.73]
Wang 2019
– 0.2169 0.1568 36.8%
0.81 [0.59, 1.09]
Yang 2019
100.0%
0.78 [0.50, 1.21]
Subtotal (95% CI)
Heterogeneity: Tau2 = 0.12; Chi2 = 8.30, df = 2 (P = 0.02); I2 = 76%
Test for overall effect: Z = 1.11 (P = 0.27)
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FIG. 3 Forest plots of pooled preoperative prognostic factors from studies reporting early recurrence or 2-year DFS after curative-intent
intrahepatic cholangiocarcinoma (iCCA) resection

estimates are derived mostly from a reliable final surgical
pathology report. This could be a partial reason why our
meta-analysis did not show any preoperative factors to be a
significantly associated with ER or 24-month DFS. Thus,
future studies should also include models exclusively
analyzing the preoperative risk factors.
Several statistical assumptions made for the meta-analysis involved pooling studies reporting in HRs only,
combining ER time points for outcomes ranging from 12 to
24 months, using a mix of adjusted and unadjusted estimates for meta-analyses, and pooling ER outcomes with a
24-month DFS. These limitations could have contributed to
the substantial heterogeneity observed in the HBV group
meta-analysis (I22 = 76%). Subgroup analysis could not be
performed for the HBV group due to a low number of
studies (n =3). Meta-analysis was not feasible for other
important prognostic factors such as CA19-9 because their
effect estimates using the same definition were reported in
fewer than two studies. Despite these limitations, pooling
evidence from available observational studies enabled us to
synthesize relevant and generalizable risk factors.24
CONCLUSION
This review provides a synthesized summary of the
prognostic factors for ER and 24-month DFS for iCCA
after curative-intent surgery. These findings could allow for
improved surveillance, prognostication, and treatment
decision-making for patients with resectable iCCAs.

Further well-designed prospective studies are needed to
explore prognostic factors for ER of iCCA focusing on
preoperative variables.
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exp common hepatic duct/ [ Embase ]
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58

hemihepatectom*.mp.

2561

11

exp bile ducts, intrahepatic/ or bile canaliculi/

9512

59

hemi-hepatectom*.mp.

245

12

intrahepatic*.mp.

55646

60

lobectom*.mp.

48019

13
14

intra-hepatic*.mp.
or/9-13 [ Intrahepatic ]

2331
58236

61

(minimal* adj3 invasiv*).mp.

136671

62

Hepatectomy/

46903

15

8 and 14 [ Cholangiocarcinoma ? Intrahepatic ]

9378

63

(excis* adj8 (liver? or hepat*)).mp.

3790

16

cancer recurrence/ [ Embase ]

198371

64

transplant*.mp.

1017819

17

Recurrence/

162127

65

graft*.mp.

760033

18

Neoplasm Recurrence, Local/

32106

66

allograft*.mp.

124364

19

recidiv*.mp.

17123

67

or/41-66 [ Surgery ]

7542943

20

recur*.mp.

1142400
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3780

21

recur*.kw.

56619
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recrudescen*.mp,kw.
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69

40 and 67 [ Cholangiocarcinoma ? Intrahepatic ?
Recurrence ? Surgery ]
(early or earlier or earliest).mp.

23

relaps*.mp,kw.

389938

70

(time adj3 recur*).mp.

18762

24

Disease-Free Survival/

88302

71

(time adj3 relaps*).mp.

10271

25

Survival Analysis/

25936

72

time factor/ [ Embase ]

38147

26

Survival Rate/

260984

73

Time Factors/

30856

27

(progress* adj2 surviv*).mp,kw.

138109

74

or/69-73 [ Early ]

2709595

28

(diseas* adj2 surviv*).mp,kw.
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2652920
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#
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11

intrahepatic*.mp.

1727

12

intra-hepatic*.mp.

116

13

or/7-12 [ Intrahepatic ]

1834

14

6 and 13 [ Intrahepatic Cholangiocarcinoma ]

284

15

cancer recurrence/ [ Embase ]

0

16

Recurrence/

11985

17

Neoplasm Recurrence, Local/

4203

18

recidiv*.mp.
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19

recur*.mp.
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20
21

recur*.kw.
recrudescen*.mp,kw.
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relaps*.mp,kw.

42923
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Disease-Free Survival/
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24

Survival Analysis/
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Survival Rate/
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(progress* adj2 surviv*).mp,kw.
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27

(diseas* adj2 surviv*).mp,kw.
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28

(surviv* adj2 analy*).mp,kw.
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29

(rate? adj2 surviv*).mp,kw.
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30

‘‘cancer free’’.mp,kw.
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31

exp Neoplasm Metastasis/

5231

32

metastasis/ [ Embase ]

3235

33

Micrometast*.mp,kw.
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34

Micro-metast*.mp,kw.
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35
36

metasta*.mp,kw.
secondary.mp,kw.
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(animal or animals or ape or apes or baboon or
baboons or bat or bats or bird or birds or boar or
boars or bonobo or bonobos or bovine or camel or
camels or canine or canines or cat or cats or cattle
or chicken or chickens or chimpanzee or
chimpanzees or dog or dogs or dromedary or
dromedaries or duck or ducks or equine or equines
or feline or felines or ferret or ferrets or frog or
frogs or fowl or fowls or goat or goats or hare or
hares or hen or hens or horse or horses or lamb or
lambs or livestock or macaque or macaques or
mandrill or mandrills or mice or mink or minks or
monkey or monkeys or mouse or murine or ovine
or pig or pigs or piglet or piglets or poultry or
porcine or orangutan or orangutans or rabbit or
rabbits or rat or rats or rodent or rodents or sheep or
swine or tamarin or tamarins or tiger or tigers or
veterinary or veterinarian or veterinarians or
waterfowl or waterfowls or weasel or weasels or
veterinar* or (veterinar* or fish or shellfish)).ti,jw.

3311878

77

75 not 76

536

78

(human* or patient? or man or mankind or men or
women or woman or adult*).ti,jw.
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79

75 and 78

100

80

limit 75 to human

516

81

77 or 79 or 80 [ Limited to human ]

537

82

limit 81 to (conference abstracts or (books or
chapter or conference abstract or ‘‘conference
review’’) or (book or book series or conference
proceeding))
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37

metastasectom*.mp,kw.

201

83

81 not 82

343

38

or/15-37 [ Recurrence & related terms ]

401976

84

81 not (conference abstract or conference review).pt.

345

39

221

85

83 or 84

345

14 and 38 [ Intrahepatic Cholangiocarcinoma ?
Recurrence ]

86

remove duplicates from 85

336

40

exp General Surgery/ [ Embase ]
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41

hemihepatectomy/ [ Embase ]

0

42

liver lobectomy/ or partial hepatectomy/ [ Embase ]

0

43

exp Surgical Procedures, Operative/

117422

CCTR-Cochrane Central Register of Controlled Trials
2014 to Present

44

su.fs.
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45

(surgery or surgeries or surgical* or operat* or
laparoscop* or resect* or reresect* or
reoperat*).mp.
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46

cholangio*ectom*.mp.

0

1

cholangiocarcinoma/ or klatskin tumor/
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47

cholangio*ostom*.mp.

8

2

(Adenoma, Bile Duct/ or Bile Duct Neoplasms/) and
Liver Neoplasms/

34

48

hepatectom*.mp.

1602

49

hepato*ostom*.mp.

66

3

cholangiocarcinom*.mp.

795

50

metastectom*.mp.

11

4

cholangiocellular carcinoma*.mp.

21

51

necrosectom*.mp.

102

5

Klatskin*.mp.

36

52

posthepatectom*.mp.

25

6

or/1-5 [ Cholangiocarcinoma ]
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53

post-hepatectom*.mp.

35

7

Common Hepatic Duct/ and (Adenocarcinoma/ or
Adenoma, Bile Duct/ or Bile Duct Neoplasms/)

1

8

exp Bile Ducts, Intrahepatic/ [ Embase ]

39

54
55

hemihepatectom*.mp.
hemi-hepatectom*.mp.

66
9

9
10

exp Hepatic Duct, Common/ [ Embase ]
exp bile ducts, intrahepatic/ or bile canaliculi/

7
39

56

lobectom*.mp.

1595

57

(minimal* adj3 invasiv*).mp.

7047
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#
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58

Hepatectomy/
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1

cholangiocarcinom*.ti,ab.

5

59

(excis* adj8 (liver? or hepat*)).mp.

59

2

cholangiocellular carcinoma*.ti,ab.

0

60

transplant*.mp.

39642

3

(bile duct? adj2 carcinoma*).ti,ab.

0

61

graft*.mp.

32696

4

Klatskin*.ti,ab.

0

62

allograft*.mp.

4754

5

or/1-4 [ Cholangiocarcinoma ]

5

63

or/40-62 [ Surgery ]

371428

6

intrahepatic*.ti,ab.

13

64

39 and 63 [ Intrahepatic Cholangiocarcinoma ?
Recurrence ? Surgery ]

143

7

intra-hepatic*.ti,ab.

2

8

or/6-7 [ Intrahepatic ]

15

65

(early or earlier or earliest).mp.

143194

9

5 and 8 [ Cholangiocarcinoma ? Intrahepatic ]

2

66

(time adj3 recur*).mp.

3139

10

recidiv*.ti,ab.

8

67

(time adj3 relaps*).mp.

2760

68

time factor/ [ Embase ]

65250

11
12

recur*.ti,ab.
recur*.kw.

662
317

69

Time Factors/

65250

13

recrudescen*.ti,ab.

0

70

or/65-69 [ Early ]

204401

14

relaps*.ti,ab.

354

71

64 and 70 [ Intrahepatic Cholangiocarcinoma ?
Recurrence ? Surgery ? Early ]

23

15

(progress* adj2 surviv*).ti,ab.

120

(animal or animals or ape or apes or baboon or
baboons or bat or bats or bird or birds or boar or
boars or bonobo or bonobos or bovine or camel or
camels or canine or canines or cat or cats or cattle or
chicken or chickens or chimpanzee or chimpanzees
or dog or dogs or dromedary or dromedaries or duck
or ducks or equine or equines or feline or felines or
ferret or ferrets or frog or frogs or fowl or fowls or
goat or goats or hare or hares or hen or hens or horse
or horses or lamb or lambs or livestock or macaque
or macaques or mandrill or mandrills or mice or
mink or minks or monkey or monkeys or mouse or
murine or ovine or pig or pigs or piglet or piglets or
poultry or porcine or orangutan or orangutans or
rabbit or rabbits or rat or rats or rodent or rodents or
sheep or swine or tamarin or tamarins or tiger or
tigers or veterinary or veterinarian or veterinarians
or waterfowl or waterfowls or weasel or weasels or
veterinar* or (veterinar* or fish or shellfish)).ti,jw.

10906

16

(diseas* adj2 surviv*).ti,ab.

64

17

(surviv* adj2 analy*).ti,ab.

23

18

(rate? adj2 surviv*).ti,ab.

79

19

‘‘cancer free’’.ti,ab.

1

20

Micrometast*.ti,ab.

1

21

Micro-metast*.ti,ab.

1

22

metasta*.ti,ab.

192

23

secondary.ti,ab.

1871

24

metastasectom*.ti,ab.

0

25

or/1-24 [ Recurrence ]

2871

26

9 and 25 [ Intrahepatic Cholangiocarcinoma ?
Recurrence ]

2

27

(surgery or surgeries or surgical* or operat* or
laparoscop* or resect* or reresect* or
reoperat*).ti,ab.

2047

28

cholangio*ectom*.ti,ab.

0

29
30

cholangio*ostom*.ti,ab.
hepatectom*.ti,ab.

0
3

72

Results

73

71 not 72

23

74

(human* or patient? or man or mankind or men or
women or woman or adult*).ti,jw.

517172

31

hepato*ostom*.ti,ab.

0

75

71 and 74

8

32

metastectom*.ti,ab.

0

76

73 or 75

23

33

necrosectom*.ti,ab.

2

77

(abstract or book or book article or book book or book
note or ‘‘book review’’ or book series article or book
series article in press or book series chapter or book
series conference paper or book series letter or
‘‘book series review’’ or book series short survey or
chapter or conference abstract or conference abstract
placebo controlled partly blinded crossover study in
12 sle patients or conference proceeding or
‘‘conference review’’ or journal conference abstract
or ‘‘journal conference review’’).pt.

182126

34

posthepatectom*.ti,ab.

0

35

post-hepatectom*.ti,ab.

0

36

hemihepatectom*.ti,ab.

0

37

hemi-hepatectom*.ti,ab.

0

38

lobectom*.ti,ab.

5

39

(minimal* adj3 invasiv*).ti,ab.

63

40

(excis* adj8 (liver? or hepat*)).ti,ab.

0

41

transplant*.ti,ab.

314

78

76 not 77

17

42

graft*.ti,ab.

167

79

remove duplicates from 78

16

43

allograft*.ti,ab.

18

44

or/27-43 [ Surgery ]

2363

45

26 and 44 [ Intrahepatic Cholangiocarcinoma ?
Recurrence ? Surgery ]

2

46

(early or earlier or earliest).ti,ab.
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47

(time adj3 factor*).ti,ab.

4
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48

(time adj3 recur*).ti,ab.

31

49

(time adj3 relaps*).ti,ab.
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or/46-49 [ Early ]

1234

51

45 and 50 [ Intrahepatic Cholangiocarcinoma ?
Recurrence ? Surgery ? Early ]
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25. Hayden JA, van der Windt DA, Cartwright JL, Côté P, Bombardier C. Assessing bias in studies of prognostic factors. Ann
Intern Med. 2013;158:280–6.
26. Nordic Cochrane Centre TCC. Review Manager (RevMan).
Published online 2014.
27. Parmar MKB, Torri V, Stewart L. Extracting summary statistics
to perform meta-analyses of the published literature for survival
endpoints. Stat Med. 1998;17:2815–34.
28. Higgins JPT, Thomas J, Chandler J, et al. Cochrane handbook for
systematic reviews of interventions. New York: John Wiley &
Sons; 2019.
29. Zhang XF, Beal EW, Bagante F, et al. Early versus late recurrence of intrahepatic cholangiocarcinoma after resection with
curative intent. Br J Surg. 2018;105:848–56.
30. Luvira V, Eurboonyanun C, Bhudhisawasdi V, et al. Patterns of
recurrence after resection of mass-forming type intrahepatic
cholangiocarcinomas. APJCP Asian Pacific J Cancer Prev.
2016;17:4735–9.
31. Nuzzo G, Giuliante F, Ardito F, et al. Intrahepatic cholangiocarcinoma: prognostic factors after liver resection. Updates Surg.
2010;62:11–9.

Systematic Review for iCCA Early Recurrence
32. Nickkholgh A, Ghamarnejad O, Khajeh E, et al. Outcome after
liver resection for primary and recurrent intrahepatic cholangiocarcinoma. BJS open. 2019;3:793–801.
33. Saxena A, Chua TC, Sarkar A, Chu F, Morris DL. Clinicopathologic and treatment-related factors influencing recurrence
and survival after hepatic resection of intrahepatic cholangiocarcinoma: a 19-year experience from an established Australian
hepatobiliary unit. J Gastrointest Surg. 2010;14:1128–38.
34. Hu LS, Weiss M, Popescu I, et al. Impact of microvascular
invasion on clinical outcomes after curative-intent resection for
intrahepatic cholangiocarcinoma. J Surg Oncol. 2019;119:21–9.
35. Ahn CS, Hwang S, Lee YJ, et al. Prognostic impact of hepatitis B
virus infection in patients with intrahepatic cholangiocarcinoma.
ANZ J Surg. 2018;88:212–7.
36. Sahara K, Tsilimigras DI, Toyoda J, et al. Defining the risk of
early recurrence following curative-intent resection for distal
cholangiocarcinoma. Ann Surg Oncol. 2021;2021:1–9.
37. Shimoda M, Tago K, Shiraki T, et al. Risk factors for early
recurrence of single lesion hepatocellular carcinoma after curative resection. World J Surg. 2016;40:2466–71.
38. Mavros MN, Economopoulos KP, Alexiou VG, Pawlik TM.
Treatment and prognosis for patients with intrahepatic

39.

40.

41.

42.

cholangiocarcinoma: systematic review and meta-analysis. JAMA
Surg. 2014;149:565–74.
Primrose JN, Neoptolemos J, Palmer DH, et al. Capecitabine
compared with observation in resected biliary tract cancer
(BILCAP): a randomised, controlled, multicentre, phase 3 study.
Lancet Oncol. 2019;20:663–73.
Lamarca A, Barriuso J, McNamara MG, Valle JW. Molecular
targeted therapies: ready for ‘‘prime time’’ in biliary tract cancer.
J Hepatol. 2020;73:170–85.
Liang W, Xu L, Yang P, et al. Novel nomogram for preoperative
prediction of early recurrence in intrahepatic cholangiocarcinoma. Front Oncol. 2018;8:360.
Zhao L, Ma X, Liang M, et al. Prediction for early recurrence of
intrahepatic mass-forming cholangiocarcinoma: quantitative
magnetic resonance imaging combined with prognostic
immunohistochemical markers. Cancer Imag. 2019;19:49.

Publisher’s Note Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.

